New Pancreatic Cancer Drug Nearly Doubles SurvivalNew Pancreatic Cancer Drug Nearly Doubles SurvivalNew Pancreatic Cancer Drug Nearly Doubles Survival 

Gemini / GoogleAn experimental drug that could be a breakthrough in the treatment of one of the deadliest known cancers is driving demand at clinics while awaiting full government approval. Daraxonrasib, a drug that targets the gene mutation behind most pancreatic cancer diagnoses, was given the green light to begin an early access program for some patients on April 30 by the Food and Drug Administration.